BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 12958359)

  • 1. Self-inhibition of synthesis and antigen presentation by Epstein-Barr virus-encoded EBNA1.
    Yin Y; Manoury B; Fåhraeus R
    Science; 2003 Sep; 301(5638):1371-4. PubMed ID: 12958359
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunology. Hide and seek in the peptidome.
    Yewdell JW
    Science; 2003 Sep; 301(5638):1334-5. PubMed ID: 12958347
    [No Abstract]   [Full Text] [Related]  

  • 3. Avoiding proteasomal processing: the case of EBNA1.
    Dantuma NP; Sharipo A; Masucci MG
    Curr Top Microbiol Immunol; 2002; 269():23-36. PubMed ID: 12224511
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epstein Barr virus-encoded EBNA1 interference with MHC class I antigen presentation reveals a close correlation between mRNA translation initiation and antigen presentation.
    Apcher S; Daskalogianni C; Manoury B; Fåhraeus R
    PLoS Pathog; 2010 Oct; 6(10):e1001151. PubMed ID: 20976201
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Messenger RNA sequence rather than protein sequence determines the level of self-synthesis and antigen presentation of the EBV-encoded antigen, EBNA1.
    Tellam JT; Lekieffre L; Zhong J; Lynn DJ; Khanna R
    PLoS Pathog; 2012 Dec; 8(12):e1003112. PubMed ID: 23300450
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Endogenous presentation of CD8+ T cell epitopes from Epstein-Barr virus-encoded nuclear antigen 1.
    Tellam J; Connolly G; Green KJ; Miles JJ; Moss DJ; Burrows SR; Khanna R
    J Exp Med; 2004 May; 199(10):1421-31. PubMed ID: 15148340
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of ubiquitin/proteasome-dependent protein degradation by the Gly-Ala repeat domain of the Epstein-Barr virus nuclear antigen 1.
    Levitskaya J; Sharipo A; Leonchiks A; Ciechanover A; Masucci MG
    Proc Natl Acad Sci U S A; 1997 Nov; 94(23):12616-21. PubMed ID: 9356498
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of antigen presentation by the glycine/alanine repeat domain is not conserved in simian homologues of Epstein-Barr virus nuclear antigen 1.
    Blake NW; Moghaddam A; Rao P; Kaur A; Glickman R; Cho YG; Marchini A; Haigh T; Johnson RP; Rickinson AB; Wang F
    J Virol; 1999 Sep; 73(9):7381-9. PubMed ID: 10438828
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting of EBNA1 for rapid intracellular degradation overrides the inhibitory effects of the Gly-Ala repeat domain and restores CD8+ T cell recognition.
    Tellam J; Sherritt M; Thomson S; Tellam R; Moss DJ; Burrows SR; Wiertz E; Khanna R
    J Biol Chem; 2001 Sep; 276(36):33353-60. PubMed ID: 11435434
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD8 T cell recognition of endogenously expressed epstein-barr virus nuclear antigen 1.
    Lee SP; Brooks JM; Al-Jarrah H; Thomas WA; Haigh TA; Taylor GS; Humme S; Schepers A; Hammerschmidt W; Yates JL; Rickinson AB; Blake NW
    J Exp Med; 2004 May; 199(10):1409-20. PubMed ID: 15148339
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting Epstein-Barr virus nuclear antigen 1 (EBNA1) through the class II pathway restores immune recognition by EBNA1-specific cytotoxic T lymphocytes: evidence for HLA-DM-independent processing.
    Khanna R; Burrows SR; Steigerwald-Mullen PM; Moss DJ; Kurilla MG; Cooper L
    Int Immunol; 1997 Oct; 9(10):1537-43. PubMed ID: 9352359
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human CD4(+) T lymphocytes consistently respond to the latent Epstein-Barr virus nuclear antigen EBNA1.
    Münz C; Bickham KL; Subklewe M; Tsang ML; Chahroudi A; Kurilla MG; Zhang D; O'Donnell M; Steinman RM
    J Exp Med; 2000 May; 191(10):1649-60. PubMed ID: 10811859
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A yeast-based assay identifies drugs that interfere with immune evasion of the Epstein-Barr virus.
    Voisset C; Daskalogianni C; Contesse MA; Mazars A; Arbach H; Le Cann M; Soubigou F; Apcher S; Fåhraeus R; Blondel M
    Dis Model Mech; 2014 Apr; 7(4):435-44. PubMed ID: 24558096
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Repeat sequence of Epstein-Barr virus-encoded nuclear antigen 1 protein interrupts proteasome substrate processing.
    Zhang M; Coffino P
    J Biol Chem; 2004 Mar; 279(10):8635-41. PubMed ID: 14688254
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of an human leucocyte antigen A2-restricted Epstein-Barr virus nuclear antigen-1-derived cytotoxic T-lymphocyte epitope.
    Marescotti D; Destro F; Baldisserotto A; Marastoni M; Coppotelli G; Masucci M; Gavioli R
    Immunology; 2010 Mar; 129(3):386-95. PubMed ID: 19922423
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Kaposi's sarcoma-associated herpesvirus latency-associated nuclear antigen 1 mimics Epstein-Barr virus EBNA1 immune evasion through central repeat domain effects on protein processing.
    Kwun HJ; da Silva SR; Shah IM; Blake N; Moore PS; Chang Y
    J Virol; 2007 Aug; 81(15):8225-35. PubMed ID: 17522213
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Restoration of endogenous antigen processing in Burkitt's lymphoma cells by Epstein-Barr virus latent membrane protein-1: coordinate up-regulation of peptide transporters and HLA-class I antigen expression.
    Rowe M; Khanna R; Jacob CA; Argaet V; Kelly A; Powis S; Belich M; Croom-Carter D; Lee S; Burrows SR
    Eur J Immunol; 1995 May; 25(5):1374-84. PubMed ID: 7774641
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of proteasomal degradation by the gly-Ala repeat of Epstein-Barr virus is influenced by the length of the repeat and the strength of the degradation signal.
    Dantuma NP; Heessen S; Lindsten K; Jellne M; Masucci MG
    Proc Natl Acad Sci U S A; 2000 Jul; 97(15):8381-5. PubMed ID: 10890896
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epstein-Barr virus nuclear antigen 1 evades direct immune recognition by CD4+ T helper cells.
    Mautner J; Pich D; Nimmerjahn F; Milosevic S; Adhikary D; Christoph H; Witter K; Bornkamm GW; Hammerschmidt W; Behrends U
    Eur J Immunol; 2004 Sep; 34(9):2500-9. PubMed ID: 15307182
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel cationic bis(acylhydrazones) as modulators of Epstein-Barr virus immune evasion acting through disruption of interaction between nucleolin and G-quadruplexes of EBNA1 mRNA.
    Reznichenko O; Quillévéré A; Martins RP; Loaëc N; Kang H; Lista MJ; Beauvineau C; González-García J; Guillot R; Voisset C; Daskalogianni C; Fåhraeus R; Teulade-Fichou MP; Blondel M; Granzhan A
    Eur J Med Chem; 2019 Sep; 178():13-29. PubMed ID: 31173968
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.